Corporate Research Group’s Weblog

Drugs to treat rare and often costly diseases have been among the biggest breakthroughs in the biotech and pharmaceutical field.  In this video interview, Leonard Bell, M.D., chief executive of Alexion Pharmaceuticals, discusses the market potential for Soliris, which treats a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH).

This entry was posted on Friday, October 3rd, 2008 at 3:20 pm and is filed under Pharmaceutical and Biotech. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.